ARGX
argenx SE
NasdaqGSUSDEQUITY
DELAYED
Last price
1,041.25
▲ 3.13 (0.30%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
1,038.12
Prev close
1,038.12
Day high
1,058.69
Day low
1,029.46
Volume
299.72K
Market cap
—
P/E (TTM)
—
52W range
661.85 – 1,058.69
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
+22.14%
+23.5%
1M
+12.46%
+8.7%
3M
+27.39%
+24.3%
6M
+23.14%
+12.1%
YTD
+23.64%
+11.4%
1Y
+57.31%
+37.3%
3Y
+107.14%
+33.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $4.15B | $2.19B | $1.23B | $410.75M | +89.6% |
| Operating revenue | $4.15B | $2.19B | $1.19B | $410.75M | +89.9% |
| Cost of revenue | $450.67M | $227.29M | $117.83M | $29.43M | +98.3% |
| Gross profit | $3.70B | $1.96B | $1.11B | $381.31M | +88.6% |
| Research & development | $1.36B | $983.42M | $859.49M | $663.37M | +38.7% |
| Selling, general & admin | $1.36B | $1.05B | $709.54M | $469.92M | +29.3% |
| Total operating expense | $2.65B | $1.98B | $1.53B | $1.11B | +33.7% |
| Operating income | $1.05B | -$17.84M | -$420.64M | -$723.92M | +6,010.2% |
| Net interest income | $159.01M | $155.04M | $106.48M | $22.55M | +2.6% |
| Pre-tax income | $1.28B | $85.18M | -$304.50M | -$729.31M | +1,401.1% |
| Tax provision | -$13.43M | -$747.86M | -$9.44M | -$19.72M | +98.2% |
| Net income | $1.29B | $833.04M | -$295.05M | -$709.59M | +55.1% |
| Net income to common | $1.29B | $833.04M | -$295.05M | -$709.59M | +55.1% |
| Basic EPS | 21.08 | 13.92 | -5.16 | -13.05 | +51.4% |
| Diluted EPS | 19.57 | 12.78 | -5.16 | -13.05 | +53.1% |
| EBIT | $1.28B | $87.64M | -$303.59M | -$727.12M | +1,363.5% |
| EBITDA | $1.31B | $105.17M | -$192.28M | -$622.78M | +1,146.3% |
| Basic shares | 61.30M | 59.86M | 57.17M | 54.38M | +2.4% |
| Diluted shares | 66.03M | 65.18M | 57.17M | 54.38M | +1.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $3.49B | $1.50B | $2.05B | $800.74M | +132.8% |
| Cash & short-term investments | $4.44B | $3.38B | $3.18B | $2.19B | +31.4% |
| Accounts receivable | $1.49B | $817.71M | $417.99M | $241.23M | +82.2% |
| Inventory | $473.53M | $407.23M | $310.55M | $228.35M | +16.3% |
| Total current assets | $6.90B | $4.88B | $4.12B | $2.77B | +41.3% |
| Property, plant & equipment | $48.25M | $43.52M | $22.68M | $16.23M | +10.9% |
| Goodwill & intangibles | $272.10M | $181.44M | $125.23M | $174.90M | +50.0% |
| Total assets | $8.68B | $6.20B | $4.54B | $3.13B | +40.0% |
| Total current liabilities | $1.32B | $669.92M | $422.99M | $302.28M | +97.1% |
| Total debt | $47.16M | $39.05M | $20.00M | $12.43M | +20.8% |
| Total liabilities | $1.36B | $704.24M | $444.95M | $320.56M | +93.1% |
| Retained earnings | -$279.77M | -$1.57B | -$2.40B | -$2.11B | +82.2% |
| Shareholder equity | $7.32B | $5.50B | $4.10B | $2.81B | +33.2% |
| Working capital | $5.58B | $4.21B | $3.70B | $2.47B | +32.4% |
| Net tangible assets | $7.05B | $5.32B | $3.97B | $2.64B | +32.6% |
| Shares issued | 61.88M | 60.76M | 59.19M | 55.40M | +1.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $1.05B | -$21.65M | -$425.05M | -$720.34M | +4,966.6% |
| Depreciation & amortisation | $28.10M | $17.53M | $111.31M | $104.34M | +60.3% |
| Stock-based compensation | $248.08M | $235.18M | $232.97M | $157.03M | +5.5% |
| Change in working capital | -$422.63M | -$325.17M | -$308.89M | -$375.72M | -30.0% |
| Operating cash flow | $685.19M | -$82.75M | -$420.33M | -$862.81M | +928.1% |
| Capital expenditure | -$111.68M | -$68.30M | -$43.81M | -$103.82M | -63.5% |
| Investing cash flow | $984.00M | -$717.59M | $308.21M | -$461.18M | +237.1% |
| Financing cash flow | $233.01M | $279.76M | $1.34B | $843.76M | -16.7% |
| Free cash flow | $573.51M | -$151.05M | -$464.14M | -$966.63M | +479.7% |
| End cash position | $3.49B | $1.50B | $2.05B | $800.74M | +132.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $1.51B | $1.30B | $1.29B | $1.13B | $947.96M | — | +16.7% |
| Operating revenue | $1.51B | $1.30B | $1.29B | $1.13B | $947.96M | — | +16.7% |
| Cost of revenue | $145.00M | $121.00M | $149.69M | $109.43M | $110.75M | — | +19.8% |
| Gross profit | $1.37B | $1.18B | $1.14B | $1.02B | $837.21M | — | +16.4% |
| Research & development | $486.00M | $443.00M | $371.71M | $355.65M | $327.70M | — | +9.7% |
| Selling, general & admin | $411.00M | $355.00M | $422.54M | $336.29M | $321.35M | — | +15.8% |
| Total operating expense | $876.00M | $783.00M | $778.63M | $667.57M | $633.37M | — | +11.9% |
| Operating income | $494.00M | $394.00M | $359.56M | $349.97M | $203.84M | — | +25.4% |
| Net interest income | $47.00M | $43.00M | $44.05M | $41.71M | $37.27M | — | +9.3% |
| Pre-tax income | $532.00M | $426.00M | $403.29M | $386.05M | $286.90M | — | +24.9% |
| Tax provision | $59.00M | $60.00M | -$129.66M | $41.80M | $41.54M | — | -1.7% |
| Net income | $472.00M | $366.00M | $532.95M | $344.26M | $245.36M | — | +29.0% |
| Net income to common | $472.00M | $366.00M | $532.95M | $344.26M | $245.36M | — | +29.0% |
| Basic EPS | — | 5.90 | — | 5.61 | — | 2.78 | — |
| Diluted EPS | — | 5.52 | — | 5.18 | — | 2.58 | — |
| EBIT | $533.00M | $427.00M | $404.12M | $387.05M | $288.02M | — | +24.8% |
| EBITDA | $533.00M | $427.00M | $404.12M | $387.05M | $288.02M | — | +24.8% |
| Basic shares | — | 62.06M | — | 61.37M | — | 60.98M | — |
| Diluted shares | — | 66.36M | — | 66.44M | — | 65.66M | — |
| Line item | 2026-06-30 | 2025-12-31 | 2025-06-30 | 2024-12-31 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $3.58B | $3.49B | $2.09B | $1.50B | +2.7% |
| Cash & short-term investments | $5.18B | $4.44B | $3.93B | $3.38B | +16.8% |
| Accounts receivable | $1.83B | $1.49B | $1.13B | $817.71M | +23.0% |
| Inventory | $371.00M | $473.53M | $340.62M | $407.23M | -21.7% |
| Total current assets | $8.07B | $6.90B | $5.83B | $4.88B | +16.9% |
| Property, plant & equipment | $52.00M | $48.25M | $45.80M | $43.52M | +7.8% |
| Goodwill & intangibles | $266.00M | $272.10M | $218.98M | $181.44M | -2.2% |
| Total assets | $10.03B | $8.68B | $7.18B | $6.20B | +15.5% |
| Total current liabilities | $1.57B | $1.32B | $1.04B | $669.92M | +19.3% |
| Total debt | $47.00M | $47.16M | $43.15M | $39.05M | -0.3% |
| Total liabilities | $1.61B | $1.36B | $1.08B | $704.24M | +18.8% |
| Retained earnings | $558.00M | -$279.77M | -$1.16B | -$1.57B | +299.5% |
| Shareholder equity | $8.42B | $7.32B | $6.10B | $5.50B | +14.9% |
| Working capital | $6.49B | $5.58B | $4.79B | $4.21B | +16.4% |
| Net tangible assets | $8.15B | $7.05B | $5.88B | $5.32B | +15.6% |
| Shares issued | 62.54M | 61.88M | 61.20M | 60.76M | +1.1% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
940.67
+10.69% from price
SMA 20
903.01
+15.15% from price
SMA 50
894.64
+16.22% from price
SMA 100
850.59
+22.42% from price
SMA 200
836.54
+24.29% from price
EMA 12
954.19
+9.12% from price
EMA 26
917.30
+13.51% from price
EMA 50
892.46
+16.67% from price
RSI (14)
73.5
Overbought
MACD (12,26,9)
36.88
Hist 20.77
ATR (14)
35.14
3.38% of price
Realised vol 30D
55.7%
Annualised
Bollinger upper
1,040.46
20, 2σ
Bollinger lower
765.57
20, 2σ
50 / 200 cross
Golden
894.64 vs 836.54
Trend bias
Above 200
+24.29%
Risk profile
Beta vs SPY
0.30
Less volatile than market
Correlation to SPY
0.11
Largely independent
Realised vol 30D
55.7%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-28.6%
Peak to trough
Max drawdown 5Y
-38.2%
Peak to trough
ATR 14
35.14
3.38% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
argenx SE (ARGX) Won Its Phase 3 Myositis Trial. How Much Does the Subgroup Miss Matter?
Insider Monkey · 24h ago
HALO Stock Rises 36% in a Month: Here's What You Should Know
Zacks · 1d ago
Could argenx SE (ARGX)’s Global Scale Give it an Edge Over Zai Lab Limited American Depositary Shares (ZLAB)?
Insider Monkey · 2d ago
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
MT Newswires · 3d ago
ARGX Announces Positive Phase III Data on Vyvgart Hytrulo, Stock Up
Zacks · 4d ago
Argenx's Myositis Data Derisk Vyvgart Opportunity, Oppenheimer Says
MT Newswires · 4d ago
Argenx's Vyvgart Hytrulo Likely to Get FDA Approval for Myositis, RBC Says
MT Newswires · 4d ago
Argenx's Myositis Data Strengthen Efgartigimod Outlook, Morgan Stanley Says
MT Newswires · 4d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.